NYSE:LCTX
Lineage Cell Therapeutics, Inc.
A pre-commercial biopharmaceutical firm developing next-generation cell therapies for rare diseases and oncology with significant cash reserves to fund R&D.
Key Metrics
Investment Thesis
Bull Case
Investors might consider LCTX for its strong balance sheet featuring $45.8M in cash and equivalents, which provides a substantial runway to advance its clinical pipeline toward potential market entry. The narrowing net losses year-over-year suggest improving operational efficiency or successful cost management as the company transitions from early research to later-stage development. Success in its rare disease portfolio could unlock significant value through orphan drug exclusivity and high-margin commercial sales.
Bear Case
The stock carries extreme risk given the persistent net losses of $18.6M and a massive retained earnings deficit of -$403.5M, signaling that current operations are not self-sustaining without external funding. Revenue has been volatile and declining from $14.7M in 2022 to $9.5M in 2024, raising concerns about the stability of its partnership agreements or milestone achievements. The lack of positive operating profit and heavy reliance on financing cash flow indicate that any failure in clinical trials could lead to a rapid depletion of resources and potential bankruptcy.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. (LCTX) is a biopharmaceutical company focused on developing innovative cell and gene therapies to treat serious diseases. The company operates within the advanced therapy medicinal products sector, primarily serving patients with rare genetic disorders and oncology indications through its proprietary platforms. Its revenue streams derive from clinical trial milestones, strategic partnerships, and potential commercialization of its engineered immune cells.
Analysis
Management Discussion
Recent financial performance highlights a challenging but stable burn rate, with net profit narrowing from -$21.5M in 2023 to -$18.6M in 2024 as revenue modestly increased to $9.5M. The company successfully extended its cash runway by generating positive financing cash flow of $35.9M, resulting in a net change in cash of $10.4M and ending with $46.4M in liquidity. However, the continued negative operating profit of -$21.5M underscores the high cost of research and development relative to current commercial returns.
Industry Overview
The cell and gene therapy industry is characterized by high barriers to entry, lengthy regulatory approval processes, and enormous capital requirements for bringing products to market. Companies in this space often operate with negative cash flows until their key assets receive regulatory approval and begin generating commercial revenue from paying patients or payers. Recent trends show consolidation among smaller biotechs and a shift toward partnerships with larger pharmaceutical companies to share development risk.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $14.7M | $8.9M | $9.5M |
| Cost of Revenue | $728.0K | $671.0K | $334.0K |
| Gross Profit | $14.0M | $8.3M | $9.2M |
| Operating Expenses | $36.5M | $33.0M | $30.6M |
| Operating Income | $-22.5M | $-24.7M | $-21.5M |
| R&D | $14.0M | $15.7M | $12.5M |
| G&A | $22.5M | $17.3M | $18.2M |
| Stock-Based Comp | $4.3M | $4.6M | $5.1M |
| D&A | $582.0K | $562.0K | $587.0K |
| Amortization | $145.0K | $130.0K | $22.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-3.3M | $1.5M | $2.9M |
| Pre-Tax Income | $-25.8M | $-23.3M | $-18.6M |
| Income Tax | $541.0K | $-1.8M | $0 |
| Continuing Ops | $-26.4M | $-21.5M | $-18.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-26.4M | $-21.5M | $-18.6M |
| Minority Interest | $-80.0K | $7.0K | $27.0K |
| Net to Common | $-26.3M | $-21.5M | $-18.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $60.0M | $38.4M | $51.0M |
| Cash & Equivalents | $11.4M | $35.4M | $45.8M |
| Marketable Securities | $46.5M | $50.0K | $2.0M |
| Accounts Receivable | — | $745.0K | $638.0K |
| Prepaid Expenses | $1.8M | $2.2M | $2.6M |
| Other Current Assets | $297.0K | $0 | $0 |
| Long-Term Assets | $63.7M | $62.6M | $62.2M |
| PP&E (Net) | $5.7M | $4.8M | $2.3M |
| Intangibles | $46.7M | $46.6M | $46.5M |
| Goodwill | $10.7M | $10.7M | $10.7M |
| Operating Leases | — | — | $2.1M |
| Other LT Assets | $627.0K | $577.0K | $614.0K |
| Total Assets | $123.7M | $101.0M | $113.2M |
| Current Liabilities | $19.0M | $18.0M | $14.0M |
| Accounts Payable | $2.4M | $2.0M | $1.2M |
| Current Leases | $916.0K | $830.0K | $1.1M |
| Deferred Revenue | $38.7M | $10.8M | — |
| Other Current Liab | $-26.9M | $3.2M | $10.5M |
| Long-Term Liabilities | $32.7M | $21.0M | $22.2M |
| LT Operating Leases | $2.9M | $2.0M | $1.3M |
| Other LT Liab | $29.9M | $19.1M | $20.9M |
| Total Liabilities | $51.7M | $39.0M | $36.2M |
| Shareholders' Equity | $71.9M | $62.0M | $77.0M |
| Retained Earnings | $-363.4M | $-384.9M | $-403.5M |
| AOCI | $-3.6M | $-3.1M | $-2.9M |
| Total L&E | $123.7M | $101.0M | $113.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-26.4M | $-21.5M | $-18.6M |
| Non-Cash Adjustments | $110.2M | $2.0M | $5.4M |
| Working Capital Changes | $-82.8M | $-9.1M | $-10.0M |
| Cash from Operations | $1.1M | $-28.6M | $-23.1M |
| Capital Expenditures | $413.0K | $674.0K | $565.0K |
| Cash from Investing | $-46.2M | $46.4M | $-2.3M |
| Cash from Financing | $1.6M | $6.4M | $35.9M |
| FX Effect | $-873.0K | $-250.0K | $-95.0K |
| Net Change in Cash | $-44.3M | $24.1M | $10.4M |
| Beginning Cash | $56.3M | $11.9M | $36.0M |
| Ending Cash | $11.9M | $36.0M | $46.4M |
Frequently Asked Questions
How does Lineage Cell Therapeutics, Inc. make money?
The company's financial profile suggests a heavy reliance on research and development activities, with operating expenses significantly outweighing current revenue. Revenue is likely driven by collaboration agreements, milestone payments from partners, and grants rather than direct product sales, typical of entities in the late-stage clinical development phase. Intangible assets and goodwill indicate substantial prior acquisitions or intellectual property portfolios central to its therapeutic pipeline.
What are the main risks for LCTX?
The company faces substantial financial risk due to a net loss of $18.6M and an accumulated deficit of over $400M, indicating it will likely need to raise additional capital to sustain operations. As a pre-revenue or low-revenue biotech firm, LCTX is highly susceptible to clinical trial failures, regulatory delays, or changes in reimbursement policies that could render its pipeline assets worthless. The significant portion of total assets tied up in operating net intangible assets ($46.5M) exposes the company to impairment risks if the underlying technologies do not generate expected commercial value.
What is LCTX's competitive advantage?
The company leverages a proprietary platform for engineering immune cells, potentially offering differentiated efficacy or safety profiles compared to existing therapies. With over $45 million in cash and equivalents, LCTX possesses the liquidity necessary to navigate the capital-intensive drug development cycle without immediate dilution. Its strategic focus on rare diseases often provides orphan drug exclusivity periods, allowing for higher pricing power once regulatory approval is achieved.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.